Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

ll differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from the Phase 3 trial will not coincide with the data analyses from the Phase 1 / 2 clinical trial previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the second fiscal quarter ended September ... Revenues of $53.9 million, up 18% over last year,s ... 33% over last year,s comparable quarter. Revenues ... Laboratories (AVRL) of $3.5 million, up 50% over last ...
(Date:10/22/2014)... 2014   Surefire Medical , Inc., the developer ... maximize targeted delivery of embolization agents in minimally invasive ... John R. Daniels , MD of the University ... oncologist Steven C. Katz , MD of the ... Advisory Board (SAB).    "The role of ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... and SYDNEY, Nov. 11, 2010 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled to make ... Annual Healthcare Conference on Wednesday, November 17, at 1:15 ...
... 11, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Medicine Technology:HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 2Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 3Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 4Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 5Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 6Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 7Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 8Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 9Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 10Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 11Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 12Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 13Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results 14
(Date:10/22/2014)... Hay House is pleased to announce the official ... Life (Paperback; $10.82) written by the highly esteemed Tommy Rosen, ... book is meant to help readers of all kinds end ... , Recovery 2.0 is not the average self-help book, or ... guide for what comes next. For many, Alcoholics ...
(Date:10/22/2014)... 2014 Best Cheap Hosting USA is ... The site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ... people from around the world. , “iPower is one ... and is providing various kinds of useful products for ... on offering excellent customer service and a number of ...
(Date:10/22/2014)... there are only 24 hours in a day, that doesn’t seem ... time within their busy schedules for exercise and fitness. Fortunately, one ... get in shape. Here are five ways you can reach your ... Up Your Commute , Consider riding a bike or taking the ... daily routine. If you must use your car to get to ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... Corporation (NYSE: BSX ) today announced financial results for the ... sales and earnings per share (EPS) for the second quarter and full ... are constant currency): , , ... $0.19, both in line with guidance (GAAP loss per share of $0.01) ...
... NEWTOWN, Pa., April 20 The managing director ... been invited to speak at the 45th Annual ... W. Singer will be present a talk entitled ... June 23, 2009.DIA is a pharmaceutical industry five-day ...
... the only reason lizards and other cold-blooded critters bask ... the May/June issue of Physiological and Biochemical Zoology ... need for vitamin D. , "It,s a longstanding assumption ... says Kristopher Karsten, a biologist at Texas Christian University ...
... Innovations, Inc. (Nasdaq: YDNT ) today announced that it ... on-demand web cast conference call on Tuesday, April 28, 2009 at ... call will be available through InterCall at http://tinyurl.com/ydnt1QTR09 ... will also be available through the Company,s website, www.ydnt.com ...
... 20 Insulet Corporation (Nasdaq: PODD ), ... OmniPod(R) Insulin Management System, announced plans to release its ... May 7, 2009 after the close of the financial ... p.m. Eastern Time on Thursday, May 7, 2009 to ...
... needed economic boost to primary care services for Floridians ... Speaker Nancy Pelosi joined Rep. Debbie Wasserman Schultz today ... discuss the positive impact of the American Recovery and ... $10 million in federal stimulus money to fund eight ...
Cached Medicine News:Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 2Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 3Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 4Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 5Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 6Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 7Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 8Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 9Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 10Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 11Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 12Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 13Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 14Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 15Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 16Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 17Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 18Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 19Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 20Health News:Boston Scientific Announces Results For First Quarter Ended March 31, 2009 21Health News:Study: Lizards bask for more than warmth 2Health News:Young Innovations, Inc. Provides First Quarter Conference Call Details 2Health News:Insulet Corporation to Report First Quarter 2009 Financial Results on Thursday, May 7, 2009 2Health News:Speaker Pelosi Visits Florida Health Center 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: